Description

Simple

Clinical

Overview

Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [2, 3, 5]. Aceclofenac potently inhibits the cyclo-oxygenase enzyme (COX) that is involved in the synthesis of prostaglandins, which are inflammatory mediators that cause pain, swelling, inflammation, and fever. Aceclofenac belongs to... Read more

Pharmacology

Indication

Aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Pharmacodynamic

Aceclofenac is a NSAID that inhibits both isoforms of COX enzyme, a key enzyme involved in the inflammatory cascade. COX-1 enzyme is a constitutive enzyme involved in prostacyclin production and protective functions of gastric mucosa whereas COX-2 is an inducible enzyme involved in the production of... Read more

Mechanism of action

Through COX-2 inhibition, aceclofenac downregulates the production of various inflammatory mediators including prostaglandin E2 (PGE2), IL-1β, and TNF from the arachidonic acid (AA) pathway. Inhibition of IL-6 is thought to be mediated by diclofenac converted from aceclofenac [ Read more

Absorption

Aceclofenac is rapidly and completely absorbed from the gastrointestinal tract and circulates mainly as unchanged drug following oral administration. Peak plasma concentrations are reached around 1.25 to 3 hours post-ingestion, and the drug penetrates into the synovial fluid where the concentration... Read more

Protein binding

It is reported to be highly protein-bound (>99%) [11].

Volume of distribution

The volume of distribution is approximately 25 L [11].

Clearance

The mean clearance rate is approximately 5 L/h [ Read more

Half life

The mean plasma elimination half-life is approximately 4 hours [11].

Route of elimination

The main route of elimination is via the urine where the elimination accounts for 70-80% of clearance of the drug [2]. Approxi... Read more

Toxicity

Some common adverse effects include gastro-intestinal disorders (dyspepsia, abdominal pain, nausea), rash, ruber, urticaria, symptoms of enuresis, headache, dizziness, and drowsiness [12... Read more

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Active peptic ulcer
      • Drugbank Id: DBCOND0107771
      • Modification Of:
        • Condition Status: active
        • Base:
          • Name: Peptic ulcer
          • Drugbank Id: DBCOND0120192
  • Regions: US
  • Patient Conditions:
      • Name: Asthma
      • Drugbank Id: DBCOND0013565
  • Hypersensitivity:
    • diclofenac
    • diclofenac analogues
  • Regions: US

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Aceclofenac
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with (R)-warfarin.
(S)-Warfarin
The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with (S)-Warfarin.
1-benzylimidazole
The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Aceclofenac.
2,5-Dimethoxy-4-ethylamphetamine
The risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Aceclofenac.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of hypertension can be increased when Aceclofenac is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Aceclofenac.
4-hydroxycoumarin
The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with 4-hydroxycoumarin.
4-Methoxyamphetamine
The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Aceclofenac.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of hypertension can be increased when Aceclofenac is combined with 5-methoxy-N,N-dimethyltryptamine.
Abacavir
Aceclofenac may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abciximab
The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Abciximab.
Abediterol
The risk or severity of hypertension can be increased when Aceclofenac is combined with Abediterol.
Acarbose
Aceclofenac may decrease the excretion rate of Acarbose which could result in a higher serum level.
Acebutolol
Aceclofenac may decrease the antihypertensive activities of Acebutolol.
Acemetacin
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Acemetacin.
Acenocoumarol
The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Acenocoumarol.
Acepromazine
The risk or severity of hypertension can be increased when Acepromazine is combined with Aceclofenac.
Acetaminophen
The risk or severity of adverse effects can be increased when Acetaminophen is combined with Aceclofenac.
Acetazolamide
Acetazolamide may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy.
Acetohexamide
The protein binding of Acetohexamide can be decreased when combined with Aceclofenac.
12 References
  1. 1 . Raza K, Kumar M, Kumar P, Malik R, Sharma G, Kaur M, Katare OP: Topical delivery of aceclofenac: challenges and promises of novel drug delivery systems. Biomed Res Int. 2014;2014:406731. doi: 10.1155/2014/406731. Epub 2014 Jun 18.PubMed: 25045671
  2. 2 . Legrand E: Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57.PubMed: 15163279
  3. 3 . Pareek A, Chandurkar N: Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis. Curr Med Res Opin. 2013 Jul;29(7):849-59. doi: 10.1185/03007995.2013.795139. Epub 2013 Apr 30.PubMed: 23581533
  4. 4 . Moore RA, Derry S, McQuay HJ: Single dose oral aceclofenac for postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007588. doi: 10.1002/14651858.CD007588.pub2.PubMed: 19588436
  5. 5 . Pareek A, Chandurkar N, Gupta A, Sirsikar A, Dalal B, Jesalpura B, Mehrotra A, Mukherjee A: Efficacy and safety of aceclofenac-cr and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study. J Pain. 2011 May;12(5):546-53. doi: 10.1016/j.jpain.2010.10.013. Epub 2011 Feb 1.PubMed: 21277837
  6. 6 . Brogden RN, Wiseman LR: Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs. 1996 Jul;52(1):113-24.PubMed: 8799688
  7. 7 . Dooley M, Spencer CM, Dunn CJ: Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.PubMed: 11511027
  8. 8 . Gonzalez-Alvaro I, Carmona L, Diaz-Gonzalez F, Gonzalez-Amaro R, Mollinedo F, Sanchez-Madrid F, Laffon A, Garcia-Vicuna R: Aceclofenac, a new nonsteroidal antiinflammatory drug, decreases the expression and function of some adhesion molecules on human neutrophils. J Rheumatol. 1996 Apr;23(4):723-9.PubMed: 8730134
  9. 9 . Ghosh S, Barik BB: A Comparative Study of the Pharmacokinetics of Conventional and Sustained-release Tablet Formulations of Aceclofenac in Healthy Male Subjects Tropical Journal of Pharmaceutical Research. 2010 September 1;9(4):395-399.PubMed:
  10. 10 . Dahiya S, Kaushik A, Pathak K: Improved Pharmacokinetics of Aceclofenac Immediate Release Tablets Incorporating its Inclusion Complex with Hydroxypropyl-beta-Cyclodextrin. Sci Pharm. 2015 Feb 2;83(3):501-10. doi: 10.3797/scipharm.1509-07. Print 2015 Jul-Sep.PubMed: 26839834
  11. 11 . UK Medicines and Healthcare products Regulatory Agency: ACECLOFENAC 100MG TABLETS product information Link
  12. 12 . DailyMed: CLANZA CR- aceclofenac tablet, film coated Link